Tarsus Pharmaceuticals
TARS
73.61
-0.50
-0.67%
Tarsus Pharmaceuticals
US · TARS
#2389 by market cap
Listed 2020
73.61
-0.50
-0.67%
Live - 5344 symbols - heartbeat 460s ago
· 2026-10-08 07:01
Pre-market
73.46
-0.20%
After-hours
73.61
0.00%
- Market cap
- 3.44B
- P/E (TTM)i
- -68.79
- P/Bi
- 9.93
- EPSi
- -1.59
- Div yieldi
- 0.00%
- 52W posi
- 52%
Reader sentiment
Are you bullish or bearish on TARS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 9.60, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +146.71% YoY
Margins
- Gross margin
- 93.20%
- Operating margin
- -15.72%
- Net margin
- -14.72%
Key ratios & quality
- Altman Z-Scorei
- 9.60
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M |
| Gross profit | -- | -- | 0 | 54.95M | 24.86M | 15.85M | 170.13M | 420.68M |
| Selling & admin expenses | 449.00K | 1.14M | 8.17M | 25.40M | 44.95M | 108.70M | 237.31M | 427.32M |
| Research & development | 901.00K | 3.16M | 18.83M | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M |
| Operating profit | -1.35M | -4.30M | -27.00M | -12.16M | -62.71M | -143.16M | -120.57M | -70.97M |
| Pretax profit | -1.32M | -4.67M | -26.81M | -13.77M | -62.10M | -135.89M | -115.55M | -64.36M |
| Tax | 1.00K | 1.00K | 1.00K | 55.00K | -4.00K | 0 | 0 | 2.06M |
| Net profit | -1.32M | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M | -115.55M | -66.42M |
| Basic EPS | 0 | -2 | -4 | -1 | -3 | -5 | -3 | -2 |
| Diluted EPS | -0.31 | -1.98 | -4.32 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 78.34M | 102.66M | 118.70M | 151.67M | 162.05M | 173.91M |
| Gross profit | 73.12M | 96.42M | 110.39M | 140.74M | 152.66M | 161.80M |
| Selling & admin expenses | 85.00M | 103.01M | 108.63M | 130.68M | 136.43M | 150.70M |
| Research & development | 14.41M | 15.59M | 16.28M | 18.04M | 22.35M | 31.01M |
| Operating profit | -26.28M | -22.18M | -14.53M | -7.98M | -6.12M | -19.91M |
| Pretax profit | -25.12M | -20.34M | -12.59M | -6.31M | -4.62M | -15.84M |
| Tax | 0 | 0 | -- | -- | 2.35M | 2.72M |
| Net profit | -25.12M | -20.34M | -12.59M | -8.37M | -6.97M | -18.55M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.64 | -0.48 | -0.30 | -0.20 | -0.16 | -0.43 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.38M | 58.03M | 170.66M | 175.95M | 225.38M | 256.13M | 356.71M | 522.78M |
| Cash & ST investments | 2.36M | 57.95M | 168.13M | 171.82M | 217.03M | 227.44M | 291.38M | 417.27M |
| Inventory | -- | -- | -- | -- | 0 | 3.11M | 2.62M | 4.37M |
| Total assets | 2.39M | 58.32M | 171.97M | 178.91M | 227.86M | 265.49M | 376.99M | 562.16M |
| Total current liabilities | 179.00K | 819.00K | 5.39M | 11.48M | 15.43M | 36.94M | 80.61M | 135.70M |
| Short-term debt | -- | 64.00K | 282.00K | 1.31M | 721.00K | 398.00K | 608.00K | -- |
| Long-term debt | -- | -- | -- | -- | 19.43M | 29.82M | 71.85M | 72.44M |
| Total liabilities | 3,743,000.00 | 64,321,000.00 | 5,992,000.00 | 12,177,000.00 | 34,963,000.00 | 68,503,000.00 | 152,457,000.00 | 218,732,000.00 |
| Total equity | -1.35M | -6.01M | 165.98M | 166.73M | 192.90M | 196.99M | 224.53M | 343.43M |
| Retained earnings | -1.36M | -6.03M | -32.85M | -46.67M | -108.76M | -244.66M | -360.21M | -426.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 480.77M | 474.43M | 501.70M | 522.78M | 537.23M | 561.99M |
| Cash & ST investments | 407.92M | 381.14M | 401.84M | 417.27M | 388.73M | 449.69M |
| Inventory | 2.71M | 3.87M | 3.84M | 4.37M | 4.57M | 4.38M |
| Total assets | 500.75M | 494.99M | 534.56M | 562.16M | 581.14M | 611.14M |
| Total current liabilities | 86.31M | 90.25M | 117.05M | 135.70M | 143.51M | 175.75M |
| Short-term debt | 384.00K | 317.00K | 80.00K | -- | -- | -- |
| Long-term debt | 71.98M | 72.13M | 72.28M | 72.44M | 72.60M | 72.76M |
| Total liabilities | 158,292,000.00 | 162,382,000.00 | 199,479,000.00 | 218,732,000.00 | 232,184,000.00 | 264,410,000.00 |
| Total equity | 342.46M | 332.61M | 335.08M | 343.43M | 348.95M | 346.73M |
| Retained earnings | -385.33M | -405.67M | -418.26M | -426.63M | -433.60M | -452.15M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.18M | -3.67M | -21.14M | 3.75M | -49.03M | -117.49M | -83.03M | -12.45M |
| Depreciation & amortization | 1.00K | 37.00K | 96.00K | 312.00K | 326.00K | 877.00K | 1.23M | 1.82M |
| Free cash flow | -1.19M | -3.85M | -21.59M | 3.16M | -49.54M | -123.00M | -89.59M | -22.31M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 91.67M | 0 | 74.35M | 118.60M | 98.29M | 134.77M |
| Ending cash balance | 2.38M | 57.97M | 168.15M | 171.33M | 71.66M | 224.95M | 97.38M | 186.20M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -20.65M | -29.39M | 18.26M | 19.33M | -24.65M | 61.22M |
| Depreciation & amortization | 460.00K | 453.00K | 460.00K | 443.00K | 437.00K | 1.00M |
| Free cash flow | -21.24M | -30.39M | 16.35M | 12.97M | -30.47M | 57.15M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 135.13M | -354.00K | 0 | 0 | 0 | 0 |
| Ending cash balance | 178.35M | 99.21M | 115.29M | 186.20M | 104.19M | 206.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -33.52 | -8.31 | -34.53 | -69.71 | -54.83 | -23.39 |
| ROA %i | -55.21 | -15.39 | -23.28 | -7.88 | -30.53 | -55.09 | -35.97 | -14.14 |
| ROIC %i | -- | -- | -33.31 | -8.26 | -33.21 | -64.96 | -46.98 | -20.20 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -40.18 | -38.15 |
| EBIT margin %i | -- | -- | -- | -21.32 | -232.01 | -760.41 | -59.09 | -12.41 |
| FCF / sales %i | -- | -- | -- | 5.54 | -- | -- | -- | -- |
| Current ratioi | 13.31 | 70.85 | 31.68 | 15.33 | 14.61 | 6.93 | 4.42 | 3.85 |
| Quick ratioi | 13.18 | 70.80 | 31.21 | 14.98 | 14.30 | 6.64 | 4.21 | 3.72 |
| Debt / assetsi | 0.00 | 0.28 | 0.48 | 1.06 | 8.85 | 11.38 | 19.22 | 12.89 |
| LT debt / equityi | -- | -- | 0.33 | 0.35 | 10.07 | 15.14 | 32.00 | 21.09 |
| Interest coveragei | -- | -- | -- | -- | -27.24 | -41.14 | -14.52 | -6.72 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 47.49 | 159.54 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -33.98 | -31.46 | -28.35 | -23.39 | -13.96 | -13.68 |
| ROA %i | -24.69 | -21.10 | -17.82 | -14.14 | -8.92 | -8.40 |
| ROIC %i | -31.01 | -27.08 | -24.58 | -20.20 | -12.66 | -12.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -41.24 | -28.20 | -19.86 | -12.41 | -6.66 | -5.15 |
| FCF / sales %i | -- | -- | -- | -- | -- | 9.24 |
| Current ratioi | 5.57 | 5.26 | 4.29 | 3.85 | 3.74 | 3.20 |
| Quick ratioi | 5.47 | 4.89 | 4.07 | 3.72 | 3.53 | 3.12 |
| Debt / assetsi | 14.45 | 14.64 | 13.54 | 12.89 | 12.49 | 11.91 |
| LT debt / equityi | 21.02 | 21.69 | 21.57 | 21.09 | 20.80 | 20.99 |
| Interest coveragei | -11.24 | -9.63 | -8.60 | -6.72 | -4.32 | -3.84 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Therapeutics100.00%
Quote time 2026-10-08 07:01:30 · For reference only, not investment advice and not tailored to your situation.